Sofinnova Partners Secures Funding for Next Wave of Life Sciences Innovation

European venture capital firm Sofinnova Partners has raised €1.2 billion across its platform of investment strategies over the past year, including more than €1 billion secured in the last quarter. This achievement brings the firm’s assets under management (AUM) to more than €4 billion, solidifying its position as a leading backer of transformative innovation in healthcare and sustainability.

“All seven of Sofinnova’s investment strategies—from incubation to later-stage growth, spanning biotech, medtech, industrial biotech and digital medicine—have capital to back the next generation of life sciences companies,” Sofinnova Partners Chairman/Managing Partner Antoine Papiernik said. “With the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world’s most pressing health and sustainability challenges.” 

Sofinnova’s latest funds have attracted significant commitments from leading institutional investors, sovereign wealth funds, corporates, and family offices, underscoring strong investor confidence in the firm’s ability to identify and nurture high-potential opportunities. 

Over the past decade, Sofinnova has built one of the most experienced, globally connected teams in life sciences investing. The firm currently comprises more than 80 professionals, including 25 investment partners with deep sector expertise. It is an international team, spanning 24 nationalities across three European offices, with presence in key innovation hubs worldwide. 

As Sofinnova expands its reach and sharpens its investment approach, it is also embracing cutting-edge technology to enhance decision-making. The firm has recently launched an AI-powered platform, built over the last five years, called Sofinnova.ai, which is transforming how it sources, analyzes, invests in and supports breakthrough science and entrepreneurs. By using advanced data analytics and machine learning, Sofinnova is further strengthening its ability to identify disruptive innovations and accelerate the development of pioneering life sciences companies. 

Sofinnova Partners is a European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm brings together a global professional team with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with entrepreneurs as a lead or cornerstone investor to develop innovations that potentially could positively impact the future. 

Founded in 1972, Sofinnova Partners is firmly established in Europe, with 50 years of experience backing more than 500 companies.